Call for EGM to Approve 90% Capital Reduction (10:1) to Cover Deficits

The 28th Extraordinary General Meeting will vote on a capital reduction (reverse stock split): 10 common shares merged into 1 (90% reduction), reason: improve financial structure by covering deficits, record date: June 5, 2026, effective June 6, 2026, expected listing of new shares June 30, 2026
Loan of 60 million won to related company KPM Tech (Jan-Mar 2026), equivalent to 14.40% of sales and 3.67% of total assets
Outside directors (Kim Kyung-han, Seo Chul-soo) recorded 81.81% board attendance, absent for internal accounting control report and representative director appointment
Pharma/biotech division: exclusive supply agreement with Emmaus Life Sciences for PGLG (SCD API), 36 billion won prepaid in 2017, 15-year contract until 2032, Emmaus must purchase at least 25% of raw material annually
RF division: expects market growth from 5G expansion, domestic market share not calculable, reference to sales of major RF companies (Wisol, Ace Technologies, GigaLane)